[31] A large study found that GLP-1 RA use was associated with lower risk of developing immune-mediated inflammatory diseases in patients with type 2 diabetes or obesity, suggesting a potential protective effect in some cohorts.[42] What the science is showing is potential for improvements: GLP-1RAs reduce blunt activation in fibroblast-like synoviocytes and improve joint inflammation and metabolic parameters in rheumatoid arthritis models and small human cohorts.[26][29][25] [31] Early clinical studies and case series in RA patients (especially those with coexisting type 2 diabetes or obesity) reported reduced disease activity scores (DAS28), lower C-reactive protein and erythrocyte sedimentation rate levels, fewer swollen joints, and diminished morning stiffness during GLP-1RA treatment, along with the expected weight reduction and improved insulin sensitivity.[31] Psoriasis showed improved PASI scores and quality-of-life metrics in patients with T2DM and psoriasis, alongside reductions in lesional skin and peripheral TNF-producing monocytes.[26] Case series show meaningful skin improvement.[26] In psoriasis and psoriatic arthritis , GLP-1RA therapy has been associated with improvements in inflammatory markers and disease severity indices
He realized that, through the media, he could bring important health information to the lives of many more people than he would be able to working in a doctors office
Use daily (AM/PM)
0.00Sold out Lycopene, B12 with Antioxidants with Carotenoids Capsule Regular price Rs
Recent years have seen a significant acceleration of research on GHK-Cu, with several clinical and preclinical studies providing new perspectives on its therapeutic applications
So the 8 to 12 week window is where physiology and clinical data meet
